Amgen Inc. (NASDAQ: AMGN) along with Zai Lab (NASDAQ: ZLAB) announced the completion of the Phase 3 FORTITUDE-101 trial assessing bemarituzumab with chemotherapy in first-line gastric cancer. The interim analysis revealed a significant enhancement in overall survival (OS) with the combined treatment compared to just chemotherapy. Nevertheless, the final analysis displayed a reduction in the initial observed survival benefit. Amgen plans to present both sets of results at an upcoming medical conference. For more details, visit Benzinga.com.